



TFW

PATENT
ATTORNEY DOCKET NO. 50164/022002

Certificate of Mailing: Date of Deposit: June 7, 2004

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Susan M. Cannon

Printed name of person mailing correspondence

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Alexis Borisy et al.	Art Unit:	1614
Serial No.:	10/617,424	Examiner:	Not yet assigned
Filed:	July 11, 2003	Customer No.:	21559
Title:	COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed. Copies of Communications from two foreign patent offices in the counterpart applications are also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office action on the merits.

If there are any other charges or any credits, please apply them to Deposit Account

No. 03-2095.

Respectfully submitted,

Date: 6/7/04



Paul T. Clark

Reg. No. 30,162

Clark & Elbing LLP

101 Federal Street

Boston, MA 02110

Telephone: 617-428-0200

Facsimile: 617-428-7045

50164.022002 Information Disclosure Statement.doc

Michael J. Belliver, Ph.D.
Reg. No. 56,608

Sheet 1 of 1SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

(37 C.F.R. § 1.98(b))

Attorney Docket No.	50164/022002
Serial No.	10/617,424
Applicant	Alexis Borisy et al.
Filing Date	July 11, 2003
Group	1614
IDS Filed	June 7, 2004
Customer No.	21559

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
	5,770,593	06/23/98	Grunicke et al.			
	6,569,853 B1	05/27/03	Borisy et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

	Lacey et al., "Activity of Benzimidazole Carbamates Against L1210 Mouse Leukaemia Cells: Correlation with <i>In Vitro</i> Tubulin Polymerization Assay," Biochemical Pharmacology 34:3603-3605 (1985), Abstract.
	Makulu et al., "Effects of Pentamidine Upon Murine Leukemia and the Walker 256 Carcinoma (W256)," American Society for Pharmacology and Experimental Therapeutic, 16:105 (1974), Abstract.
	Pourgholami et al., " <i>In Vitro</i> Inhibition of Human Liver Cancer Cells by Albendazole," Proceedings of the American Association for Cancer Research Annual Meeting 41:656 (2000), Abstract #4171.
	Ram et al., "Synthesis and Biological Activity of Certain Alkyl 5-(Alkoxy carbonyl)-1H-Benzimidazole-2-Carb-mates and Related Derivatives: A New Class of Potential Antineoplastic and Antifilarial Agents," Journal of Medicinal Chemistry and Pharmaceutical Chemistry 35:539-547 (1992), Abstract.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.